Showing results (1731-1740 of 1,857) with videos related to

Sort By:
Pageof 186
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2014
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metforminLigong Chen, Yan Shu, Xiaomin Liang, et al.
Cell Metabolism|December 17, 2013
Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cellsSharona Tornovsky-Babeay, Daniela Dadon, Oren Ziv, et al.
JCI Insight|August 4, 2022
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetesAna Luisa Perdigoto, Songyan Deng, Katherine C Du, et al.
Inflammatory Bowel Diseases|June 29, 2019
Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's DiseaseWilliams Turpin, Osvaldo Espin-Garcia, Larbi Bedrani, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 11, 2025
Gene-corrected regulatory T cell therapy for IL2RA deficiencyAlvin S Ha, Nechama Kalter, Michael Rosenberg, et al.
Environmental Research. Water|May 6, 2026
Post-wildfire water quality and aquatic ecosystem response in the U.S. Pacific Northwest: science and monitoring gapsSara Wall, Jana E Compton, Ashley A Coble, et al.
Lancet (London, England)|July 1, 2011
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialDiane K Wherrett, Brian Bundy, Dorothy J Becker, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort studyZoe Quandt, Anastasia Lucas, Samantha I Liang, et al.
Diabetes Care|February 2, 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention StudyDarrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, et al.
Pageof 186